TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

What's Going On With Royalty Pharma Stock Wednesday?

Benzinga Logo Benzinga By Vandana Singh
What's Going On With Royalty Pharma Stock Wednesday?

Royalty Pharma acquired the final portion of PTC Therapeutics' royalty on Roche's Evrysdi for $240 million upfront plus up to $60 million in milestones, giving it 100% ownership of the 8-16% tiered royalty. Evrysdi generated $1.9 billion in 2024 sales with projected growth to $2.9 billion by 2030. RPRX stock is up 53% year-to-date but down slightly on Wednesday. The company also recently acquired royalty interests in Nuvalent's cancer drugs.

Insights
RPRX   positive

Acquisition of full royalty ownership on Evrysdi, a successful drug with strong sales growth trajectory ($1.9B to $2.9B by 2030), plus recent Nuvalent royalty deal demonstrates strategic portfolio expansion and revenue diversification.